Modalis Joins Ginkgo's Technology Network
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.